Pharma BD Deal Intelligence

Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited

2014 · Acquisition/Merger · $4.0B · Complete

Announcement Sentiment

Skeptical

Sun Pharma agreed to acquire 100% of Daiichi Sankyo subsidiary Ranbaxy Laboratories in an all-stock transaction valued at approximately $4B (US$3.2B equity plus $800M assumed debt). The combination created India's largest pharmaceutical company and the world's fifth-largest generics maker; closed in calendar 2015.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Mixed

Assessment window: 10yr post-close.

Key facts

Announced Apr 07, 2014
Closed Mar 25, 2015
Deal value $4.0B
Deal type Acquisition/Merger
Therapeutic area Diversified generics
Indications Diversified generics
Key assets Generic global portfolio plus India franchise
Mechanism N/A (generics platform)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals